Yingdan Wang

Key Laboratory Of Medical Molecular Virology
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or Mpro inhibitors.

Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or Mpro inhibitors.

Journal: Journal of virology

Published: March 30, 2026

Evaluation of Poxvirus-Specific Antibody Response in Monkey Poxvirus-Negative and -Positive Cohorts.

Evaluation of Poxvirus-Specific Antibody Response in Monkey Poxvirus-Negative and -Positive Cohorts.

Journal: Vaccines

Published: June 04, 2025

Synergistic impact of macrolide resistance and H3N2 infection on M. pneumoniae outbreak in children.

Synergistic impact of macrolide resistance and H3N2 infection on M. pneumoniae outbreak in children.

Journal: Microbiology spectrum

Published: February 25, 2025

A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.

A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.

Journal: Cell discovery

Published: February 09, 2025

Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses.

Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses.

Journal: iScience

Published: July 07, 2024

A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.

A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.

Journal: Nature communications

Published: August 24, 2023

A broadly neutralizing antibody inhibits SARS-CoV-2 variants through a novel mechanism of disrupting spike trimer integrity.

A broadly neutralizing antibody inhibits SARS-CoV-2 variants through a novel mechanism of disrupting spike trimer integrity.

Journal: Cell research

Published: June 25, 2023

M2e-specific antibodies protect against influenza PR8 virus in an isotype and route dependent manner.

M2e-specific antibodies protect against influenza PR8 virus in an isotype and route dependent manner.

Journal: Journal of medical virology

Published: December 14, 2022

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.

Journal: Cell discovery

Published: March 18, 2022

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding.

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding.

Journal: Cell research

Published: February 12, 2022

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma.

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma.

Journal: Emerging microbes & infections

Published: January 10, 2022

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.

Journal: Cell discovery

Published: November 19, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026